GLP-1 Drugs Linked to Fewer Psychiatric Admissions

A US cohort study found adults with schizophrenia and Type 2 diabetes who started GLP-1 receptor agonists had lower rates of psychiatric hospitalization.

Updated on Nov. 6, 2026 in Diabetes

Bold flat-color vector editorial illustration of a coral injector pen on a teal clinical tray beside plain sample vials, representing GLP-1 drug treatment. — A U.S. cohort study of 70,257 adults with schizophrenia and Type 2 diabetes found that GLP-1 receptor agonist starters had lower rates of psychiatric hospitalization. AI Illustration. Upload story photo >

Adults with schizophrenia and Type 2 diabetes who initiated GLP-1 receptor agonists had a lower risk of psychiatric hospitalization than those who did not start these treatments. The observational study also linked the drugs to lower emergency department presentation risk in the same population.

Why it matters

People with serious mental illness often face higher rates of diabetes and worse physical health outcomes, making treatment choices with broader benefits relevant to U.S. patients and clinicians. The findings add observational evidence on how a widely used diabetes drug class may relate to mental health care use.

The observational cohort study of 70,257 adults found a weighted hazard ratio of 0.76 for psychiatric hospitalization with GLP-1 initiation compared with non-initiation (95% CI: 0.71-0.82). Because the study was observational, the results show association rather than proven cause, and the source does not address outcomes beyond two years of follow-up.

The players

Lancet Psychiatry

Lancet Psychiatry is a peer-reviewed clinical journal published by Elsevier that focuses on research in psychiatry and mental health.

The details

Researchers analyzed electronic health records from the US NeuroBlu Data repository covering 70,257 adults with schizophrenia and Type 2 diabetes, with a mean age of 53.1 years and women making up 48.2% of the cohort. Between 2018 and 2025, 12.9% of participants started GLP-1 receptor agonists, 7.1% started DPP-4 inhibitors, 7.6% started SGLT2 inhibitors, and 72.4% started none of these drugs. Participants were followed for up to two years.

2018 to 2025: Participants initiated glucose-lowering treatments during this period.
Up to 2 years: Follow-up period for study participants.
2026: The study was published in Lancet Psychiatry.

Health Landscape

GLP-1 receptor agonists were first developed as diabetes treatments and have since become widely prescribed for weight management and cardiometabolic care. This study extends their documented use into a population with serious mental illness, where diabetes is common and psychiatric outcomes are a central concern.

Patients with schizophrenia and Type 2 diabetes may want to discuss with their clinicians whether GLP-1 receptor agonists are appropriate for their care. The study is observational, so any treatment decision should rest on individual medical advice rather than these findings alone.

The takeaway

Observational evidence suggests GLP-1 receptor agonists may be associated with fewer psychiatric hospitalizations among adults with schizophrenia and Type 2 diabetes. Clinicians and patients should weigh these associations alongside other treatment factors before making decisions.